Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07447102) titled 'Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Dragonboat Biopharmaceutical Company Limited

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: Drug: BC006

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 1, 2026

Target Sample Size: 96

To know more, visit https://clinicaltrials.gov/study/NCT07447102

Published by HT Digita...